Scheduled
for March 22–24, 2027 in Singapore and Online, the conference provides a global
platform for networking, collaboration, and scientific discussions in neurology
and neuroscience.
This international event will bring together researchers, neurologists,
neuroscientists, healthcare professionals, academicians, and industry experts
from around the globe to connect, collaborate, and exchange scientific
knowledge.
Neuro Care 2027 aims to create a dynamic platform for discussing the latest
advancements, innovations, and research developments in neurology and
neuroscience.
π March 23–25, 2026
π Singapore
π’ Organized by Mathews International LLC
Your contributions, knowledge sharing, and collaboration helped create an inspiring platform for advancing neuroscience and neurological research worldwide.
π We look forward to seeing you again at our future events!
We are pleased to announce that the Final Program is now live for the upcoming joint international conferences organized by Mathews Conferences. This prestigious event brings together two leading global meetings focused on advancing research and clinical practice in brain and mental health sciences.
These conferences will bring together neurologists, psychiatrists, neuroscientists, mental health professionals, researchers, clinicians, and healthcare innovators from around the world to share groundbreaking research, emerging therapies, and innovative clinical practices.
Event Details
π Dates: March 23–25, 2026 π Location:Singapore π¨ Venue: Village Hotel Changi
The conference will be conducted in a hybrid format, allowing participants to attend in person in Singapore or virtually from anywhere across the globe.
What to Expect
The final program features a comprehensive lineup of:
Keynote presentations by leading experts
Oral and poster research sessions
Discussions on emerging neuroscience and psychiatric treatments
Networking opportunities with global professionals
Collaborative sessions on addiction medicine and mental health care
Participants will gain valuable insights into recent developments in neurology, neuroscience, psychiatry, addiction medicine, and mental health research, fostering interdisciplinary collaboration and knowledge exchange.
Register Now
We invite researchers, academicians, clinicians, and healthcare professionals to explore the final program and secure their participation in this global scientific gathering.
∙ Focus: Investigating innovative therapeutic strategies for Alzheimer's disease, one of the most challenging global neurodegenerative disorders. ∙ Clinical Challenge: Despite recent monoclonal antibody therapies, reliable disease-modifying treatments remain limited. ∙ Research Approach: Evaluation of existing drugs for repurposing in modulating key pathological hallmarks of Alzheimer’s disease. ∙ Drugs Studied: The anti-retroviral drug Raltegravir and SGLT2 inhibitors such as Empagliflozin and Dapagliflozin. ∙ Cellular Models: Experiments conducted using H4 neuroglioma and HMC3 microglia cell models to study molecular alterations induced by amyloid-beta. ∙ Key Findings:
Raltegravir significantly reduced Tau phosphorylation (p-Tau181) and modulated key kinases and phosphatases.
Reduced inflammatory signaling through downregulation of the NLRP3 inflammasome pathway.
SGLT2 inhibitors decreased oxidative stress and neuroinflammatory responses triggered by amyloid-beta. ∙ Neuroprotective Effects: Gliflozins improved cell viability and reduced apoptosis in neuronal models. ∙ Therapeutic Potential: These findings suggest promising drug-repurposing strategies for modifying disease progression in Alzheimer’s disease. ∙ Research Outlook: Provides preliminary mechanistic insights supporting further clinical exploration of these treatments.
∙ Therapeutic Focus: Exploration of Ethylmethylhydroxypyridine succinate (Mexidol®) as a neuroprotective treatment for ischemic stroke.
∙ Antioxidant Activity: The compound neutralizes superoxide radicals and enhances antioxidant enzyme activity including superoxide dismutase and glutathione peroxidase while activating the NRF2 transcription factor.
∙ Hypoxia Protection: Supports mitochondrial respiratory chain activity under low oxygen conditions and activates the succinate receptor (SUCNR1) while influencing the HIF-1Ξ± transcription factor, improving cellular resistance to hypoxia.
∙ Neuroprotective Effects: Experimental studies demonstrate reduction of neuroinflammation and apoptosis while promoting neuroplasticity, which is critical for brain recovery after stroke.
∙ Preclinical Evidence: Animal studies modeling acute focal cerebral stroke showed significant improvement in neurological symptoms and reduction in hemorrhagic lesion size in treated groups compared with placebo.
∙ Clinical Trial Results: A double-blind placebo-controlled MIR study involving 304 ischemic stroke patients demonstrated:
Significant reduction in disability using the mRS scale
Improved neurological function measured by NIHSS
Enhanced mobility via the Rivermead Index
Trends toward cognitive improvement assessed by the MoCA test
∙ Safety Profile: Adverse events were comparable between drug and placebo groups, confirming long-term safety and tolerability of sequential therapy.
∙ Clinical Impact: Findings highlight Mexidol® as a promising therapeutic strategy for improving neurological recovery and functional outcomes in ischemic stroke patients.
π¨⚕️ About the Speaker
Dr. Aleksey Shchulkin is a Professor in the Department of Pharmacology and Head of the Pharmacokinetics Laboratory at Ryazan State Medical University, Russia.
∙ Expert in pharmacokinetics and neuroprotection ∙ Leading research in drug mechanisms and therapeutic interventions for neurological disorders ∙ Active contributor to experimental and clinical studies focused on stroke therapy and neuroprotective pharmacology
Connect with global neurologists, neuroscientists, clinicians, and researchers to explore the latest innovations in brain science, stroke therapy, neurodegeneration, and neurological care.
The International Conference on Neurology and Neuroscience is set to take place on March 23–25, 2026 in Singapore & Online, bringing together leading neurologists, neuroscientists, researchers, clinicians, and healthcare innovators from around the world.
This global Neurology Conference 2026 will serve as a premier platform to discuss the latest advancements in brain research, neurological disorders, neuroimaging, neurogenetics, neurosurgery, neuroimmunology, and AI-driven innovations in neuroscience.
π§ Conference Highlights
Clinical Neurology & Neurophysiology
Neurological Diseases & Brain Disorders
Neuroimmunology & Neuroinflammation
Neuroimaging & Diagnostic Technologies
Neurosurgery & Therapeutic Innovations
Pain Management & Neuropathic Pain
Clinical Trials in Neurology
AI in Neuroscience & Digital Neurology
Participants will gain access to high-impact keynote sessions, oral and poster presentations, networking opportunities, and cutting-edge discussions shaping the future of brain health and neurological care.
